-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $48

Benzinga·01/02/2026 09:50:29
Listen to the news
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $47 to $48.